Atrium Therapeutics clears IND for ATR 1072, activates first Corventis sites for PRKAG2 syndromeAug 13Quarterly updateATR-1072Atrium Therapeutics
Atrium Therapeutics recruiting for Phase 1/2 ATR 1072 trial in PRKAG2 SyndromeJul 31Trial updateATR-1072Atrium Therapeutics
Sign inSign in